×
About 15,943 results

ALLMedicine™ Macular Degeneration Center

Research & Reviews  5,298 results

The Vitreous Proteome and Inflammatory Mediators in Ocular Inflammatory Disease
https://clinicaltrials.gov/ct2/show/NCT00331331

May 20th, 2022 - Newer therapies to treat many ocular disorders including uveitis are being considered and studied. We do not have a clear picture as to what lymphokines/chemokines are present in the vitreous or anterior chamber fluid of patients with active intra...

AMD Ryan Initiative Study (ARIS)
https://clinicaltrials.gov/ct2/show/NCT03092492

May 20th, 2022 - Objective: Late age-related macular degeneration (AMD) is the leading cause of blindness among elderly in the United States. At present, the current classification systems do not take into consideration advances in imaging technology, visual funct...

OCT-angiography follow-up of choroidal neovascularization treated with treat- and- exte...
https://doi.org/10.1177/11206721221102263
European Journal of Ophthalmology; Furino C, Albano V et. al.

May 18th, 2022 - To propose optical coherence tomography angiography (OCT-A) for the follow-up of neovascular age-related macular degeneration (nAMD) treated with a treat-and-extend (T&E) aflibercept regimen to avoid overtreatment. Retrospective, cohort, pilot stu...

Blue-light fundus autofluorescence imaging of pigment epithelial detachments.
https://doi.org/10.1038/s41433-022-02076-5 10.1016/S0161-6420(90)32619-2 10.1038/eye.1991.2 10.1136/bjo.76.3.166 10.1016/j.preteyeres.2009.08.003 10.1167/iovs.10-6678 10.1167/iovs.09-4195 10.1016/j.preteyeres.2015.05.003 10.1097/IAE.0b013e3182993f66 10.1136/bjo.64.6.412 10.1136/bjo.69.6.397 10.1016/0039-6257(88)90052-5 10.1007/BF00166756 10.1007/s00417-002-0505-8 10.1016/j.ajo.2008.10.005 10.1097/IAE.0b013e3181eef3eb 10.1111/aos.14117 10.1097/IAE.0000000000002244 10.1111/aos.14423 10.1136/bjo.79.5.407 10.1007/s003470050130 10.1007/s004170050209 10.1097/IAE.0b013e318164a907 10.1016/j.preteyeres.2020.100893 10.1016/j.exer.2017.10.018 10.1167/iovs.61.5.35 10.1136/bjo.2004.057794 10.1167/iovs.04-0430 10.1016/j.ajo.2006.11.041 10.1016/j.ajo.2005.07.037 10.1097/00006982-199414020-00006 10.1136/bjo.2003.017632 10.1016/j.ophtha.2009.12.002 10.1016/j.ophtha.2018.08.017 10.1016/j.ophtha.2017.08.030 10.1016/j.ophtha.2016.01.044 10.1016/j.ophtha.2015.07.008 10.1007/s40123-020-00291-5 10.1016/j.ophtha.2019.11.004 10.1167/iovs.14-16274 10.1167/iovs.61.8.13 10.3390/vision2040038 10.21037/aes-20-12 10.1016/j.ophtha.2005.01.003 10.1097/ICB.0b013e318074bc8c 10.1155/2011/706849 10.1016/j.ophtha.2016.12.034 10.1001/jamaophthalmol.2016.1475 10.1097/IAE.0000000000002923 10.1007/s00417-003-0796-4 10.1097/01.OPX.0000162652.85875.D2 10.1007/s00417-010-1577-5 10.1167/tvst.8.6.41 10.1016/j.ajo.2015.08.001 10.1016/S0002-9394(02)01428-9 10.1097/IAE.0000000000002580 10.1038/s41598-019-47565-y 10.1016/j.ajo.2020.04.003 10.1159/000439445 10.1016/j.survophthal.2017.03.004 10.1097/IAE.0000000000000867 10.1016/j.oret.2020.02.016
Eye (London, England); Bindewald-Wittich A, Dolar-Szczasny J et. al.

May 18th, 2022 - Pigment epithelial detachments (PEDs) occur in association with various chorioretinal diseases. With respect to the broad clinical spectrum of PEDs we describe fundus autofluorescence (FAF) characteristics of PEDs. Ninety-three eyes of 66 patients...

see more →

Guidelines  8 results

Dietary Supplements for Eye Conditions: What the Science Says
https://www.nccih.nih.gov/health/providers/digest/dietary-supplements-for-eye-conditions-science?nav=govdcd
NCCIH Clinical Digest for Health Professionals; National Center for Complementary and Integrative Health (NCCIH)

Mar 31st, 2022 - Findings from the Age-Related Eye Disease Studies (AREDS and AREDS2) suggest that dietary supplementation with antioxidant vitamins and zinc may slow the progression of age-related macular degeneration in people who have intermediate AMD and those...

First Alternative to Eye Injections for Age-related Macular Degeneration Shown Effective
https://www.aao.org/newsroom/news-releases/detail/first-alternative-to-amd-eye-injections-effective
American Academy of Ophthalmology

Nov 15th, 2021 - NEW ORLEANS, La. – An implant that delivers medication to the back of the eye was found to effectively treat age-related macular degeneration (AMD) for at least six months. This represents a vast improvement over the typical regimen of nearly mont...

Age-related Macular Degeneration: Poised for a New Treatment Era
https://www.aao.org/newsroom/news-releases/detail/age-related-macular-degeneration-new-treatment-era
American Academy of Ophthalmology

Feb 11th, 2021 - SAN FRANCISCO – For more than a decade, ophthalmologists have treated wet age-related macular degeneration (AMD) with eye injections given every month or two, and dry AMD with antioxidant vitamins. These treatments were groundbreaking when introd...

Age-Related Macular Degeneration Preferred Practice Pattern®.
https://doi.org/10.1016/j.ophtha.2019.09.024
Ophthalmology Flaxel CJ, Adelman RA et. al.

Nov 24th, 2019 - Age-Related Macular Degeneration Preferred Practice Pattern®.|2019|Flaxel CJ,Adelman RA,Bailey ST,Fawzi A,Lim JI,|standards,therapeutic use,administration & dosage,administration & dosage,diagnosis,therapy,organization & administration,standards,s...

Screening for Impaired Visual Acuity in Older Adults: Clinical Summary
https://allmedx.com/USPSTFPDF/viselderscrsumm.pdf

Feb 23rd, 2016 - Screening for Impaired Visual Acuity in Older Adults: Clinical Summary Population Adults 65 years or older who do not present with vision problems Recommendation No recommendation. Grade: I (insufficient evidence) Risk Assessment Older a...

see more →

Drugs  17 results see all →

Clinicaltrials.gov  345 results

The Vitreous Proteome and Inflammatory Mediators in Ocular Inflammatory Disease
https://clinicaltrials.gov/ct2/show/NCT00331331

May 20th, 2022 - Newer therapies to treat many ocular disorders including uveitis are being considered and studied. We do not have a clear picture as to what lymphokines/chemokines are present in the vitreous or anterior chamber fluid of patients with active intra...

AMD Ryan Initiative Study (ARIS)
https://clinicaltrials.gov/ct2/show/NCT03092492

May 20th, 2022 - Objective: Late age-related macular degeneration (AMD) is the leading cause of blindness among elderly in the United States. At present, the current classification systems do not take into consideration advances in imaging technology, visual funct...

A Study of the Efficacy, Safety, and Pharmacokinetics of A 36-Week Refill Regimen for the Port Delivery System With Ranibizumab in Patients With Neovascular Age-Related Macular Degeneration (Velodr...
https://clinicaltrials.gov/ct2/show/NCT04657289

May 16th, 2022 - Study WR42221 is a Phase IIIb, global, multicenter, randomized, visual assessor-masked study designed to assess the efficacy, safety, and pharmacokinetics of the Port Delivery System with ranibizumab (PDS) 100 mg/mL delivered every 36 weeks (Q36W)...

A Study to Evaluate the Long-Term Safety and Tolerability of Faricimab in Participants With Neovascular Age-Related Macular Degeneration
https://clinicaltrials.gov/ct2/show/NCT04777201

May 16th, 2022 - This is a multicenter long-term extension study designed to evaluate the long-term safety and tolerability of faricimab 6 milligrams (mg) administered by intravitreal injection at a personalized treatment interval to participants with neovascular ...

Evaluation of Oral Minocycline in the Treatment of Geographic Atrophy Associated With Age-Related Macular Degeneration
https://clinicaltrials.gov/ct2/show/NCT02564978

May 13th, 2022 - Objective: Age-related macular degeneration (AMD), the leading cause of blindness in people over age 65 in the United States, is a heterogeneous clinical entity in which retinal degeneration occurs predominantly in the macula in the context of agi...

see more →

News  693 results

Treatment of Exudative (Wet) Age-Related Macular Degeneration (AMD): The Knowns and the Unknowns
https://www.medscape.com/viewarticle/971151

May 11th, 2022 - While noting the considerable amount of time that has passed since anti-VEGF therapy became available for exudative (wet) age-related macular degeneration (AMD), Sunir Garg, MD, reflects upon the current knowns and unknowns regarding this frequent...

Tracking the Evolution of Management Options in Wet AMD
https://www.medscape.com/viewarticle/971149

May 9th, 2022 - Sunir Garg, MD, recalls his first patient with exudative (wet) macular degeneration during residency and the limited therapeutic options that were available to treat this condition at that time, as well as the uncomfortable conversations that he h...

White People Receive More Macular Degeneration Treatment
https://www.medscape.com/viewarticle/973605

May 6th, 2022 - DENVER, Colorado — White, non-Hispanic people get more injections than people of other races and ethnicities to treat neovascular age-related macular degeneration (nAMD), according to an analysis of a large database analysis. Black, Asian, and His...

How Home Diagnostic Tools Will Alter the Future of Wet Age-Related Macular Degeneration
https://www.medscape.com/viewarticle/971148

May 6th, 2022 - SriniVas R. Sadda, MD, looks to the future at the dawn of home diagnostics and home monitoring for patients with exudative age-related macular degeneration (wet AMD) through the promise and anticipated approval of at-home optical coherence tomogra...

Treatment of Exudative (Wet) Age-Related Macular Degeneration (AMD): The Promise of Meeting the Needs
https://www.medscape.com/viewarticle/971160

May 2nd, 2022 - In reflecting upon an array of unmet needs regarding exudative (wet) age-related macular degeneration (AMD), Sunir Garg, MD, identifies easing the treatment burden of the disease as a short-term goal. Dr Garg then details the often onerous practic...

see more →

Patient Education  16 results see all →